Skip to main content
Canna~Fangled Abstracts

Impact of CB1 receptor antagonism on skeletal muscle hypertrophy and metabolic health: a systematic review of preclinical studies

By January 27, 2025No Comments

Review
. 2025 Jan 27.

doi: 10.1007/s42000-025-00628-4.

Online ahead of print.
Newton Kleber de Abreu Júnior 1, Izabel Fabro Feltrin 1, Débora Maria Russiano Pereira 2, Poliana Penasso Bezerra 1, Aderbal S Aguiar Jr 3 4 5
Affiliations 

Abstract

The endocannabinoid system (ECS), regulating such processes as energy homeostasis, inflammation, and muscle function, centers around cannabinoid receptors, including CB1. These receptors are mainly located in the central nervous system and skeletal muscles. Hyperactivity of CB1 receptors is linked to metabolic disorders and chronic inflammation, highlighting their potential as therapeutic targets for muscle hypertrophy and metabolic health. This systematic review, registered with PROSPERO (CRD42023462735), follows PRISMA-P guidelines and uses the PICO framework. It evaluates the effects of CB1 receptor antagonism on muscle hypertrophy in animal models and cell lines. Interventions include pharmacological antagonists, genetic modifications, and exercise-induced antagonism. A comprehensive search of databases such as PubMed, EMBASE, CINAHL, and SPORTDiscus, supplemented by gray literature and reference lists, yielded 571 references. From these, ten studies were selected, involving 338 rodents, using CB1 antagonists like rimonabant and AM251. The findings suggest that CB1 receptor antagonism enhances insulin sensitivity and glucose tolerance, reduces body fat, and promotes muscle growth through pathways such as PI3K/Akt and mTOR, as well as by improving autophagy and mitochondrial function. This review proposes CB1 receptor antagonism as a promising approach for enhancing muscle hypertrophy and improving metabolic health, with potential applications in treating such conditions as obesity, type 2 diabetes, and sarcopenia. Future research should aim to standardize intervention protocols and explore integrated therapies to fully harness the benefits of CB1 modulation.

Keywords: CB1 receptor, Cannabinoid antagonism, Endocannabinoid system, Muscle growth signaling, Skeletal muscle hypertrophy

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare that they have no financial or non-financial interests, either direct or indirect, that could reasonably be perceived as influencing the work submitted for publication. This declaration covers the period of the last 3 years from the initiation of the research and the preparation of the manuscript for submission.

References

    1. Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:771–784. https://doi.org/10.1038/nrd1495 – DOI – PubMed
    1. Bellocchio L, Lafentre P, Cannich A et al (2010) Bimodal control of stimulated food intake by the endocannabinoid system. Nat Neurosci 13:281–283. https://doi.org/10.1038/nn.2494 – DOI – PubMed
    1. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R (2006) The emerging role of the Endocannabinoid System in Endocrine Regulation and Energy Balance. Endocr Rev 27:73–100. https://doi.org/10.1210/er.2005-0009 – DOI – PubMed
    1. Cavuoto P, McAinch AJ, Hatzinikolas G, Janovská A, Game P, Wittert G (2007) The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 364:105–110. https://doi.org/10.1016/j.bbrc.2007.09.099 – DOI – PubMed
    1. Cinar R, Godlewski G, Liu J, Tam J, Jourdan T, Mukhopadhyay B et al (2014) Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides. Hepatology 59:143–153. https://doi.org/10.1002/hep.26606 – DOI – PubMed

Publication types

Leave a Reply